cannabidiolic acid | 19206-65-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cannabidiolic acid
• 英文别名: 2,4-Dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-pentylbenzoic acid
• CAS: 19206-65-6
• 化学式: C₂₂H₃₀O₄
• 分子量: 358.478
• InChiKey: WVOLTBSCXRRQFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-diacetoxy-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-3-carboxylic acid 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 cannabidiolic acid
  参考文献：
  名称：

  [EN] METHODS OF SYNTHESIZING HALOGENATED CANNABINOIDS AND DERIVATIVES OF CANNABINOIDS
  [FR] PROCÉDÉS DE SYNTHÈSE DE CANNABINOÏDES HALOGÉNÉS ET DE DÉRIVÉS DE CANNABINOÏDES

  摘要：

  The technology described herein provides for the synthesis of various cannabinoids, cannabinoid derivatives, and intermediate molecules useful in the synthesis of cannabinoids. For example, the technology described herein provides methods for synthesis of cannabinoids halogenated at the 4-position.

  公开号：

  WO2022192582A1

文献信息

• [EN] CANNABINOID DERIVATIVES<br/>[FR] DÉRIVÉS CANNABINOÏDES
  申请人：CANOPY GROWTH CORP

  公开号：WO2021062559A1

  公开（公告）日：2021-04-08

  This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are potential carmabinoid receptor inhibitors, including CB1 and CB2 receptors. Formula (I)

  本公开涉及公式（1）中R4或R7为羧酰胺基团的卡马比诺衍生物，包括这些化合物的药物组合物以及使用卡马比诺衍生物的方法。这些化合物是潜在的卡马比诺受体抑制剂，包括CB1和CB2受体。公式（I）。
• APPARATUS FOR CANNABINOL GENERATION AND METHODS OF USING THE SAME
  申请人：AZDT Holdings, LLC

  公开号：US20210380552A1

  公开（公告）日：2021-12-09

  The present disclosure methods for producing cannabinol from Cannabis compositions. The present disclosure further provides apparatuses for the production of cannabinol from Cannabis compositions.

  本公开揭示了从大麻组分中生产大麻酚的方法。本公开进一步提供了从大麻组分生产大麻酚的装置。
• POLYFUNCTIONAL CANNABINOIDS
  申请人：Axim Biotechnologies, Inc.

  公开号：US20210332004A1

  公开（公告）日：2021-10-28

  This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

  这项发明揭示了与聚乙二醇链相连的大麻素。大麻素-聚乙二醇链分子具有一个、两个或更多个大麻素与一个、两个或更多个聚乙二醇链相连。每个大麻素-聚乙二醇链分子可能具有一种大麻素或多种大麻素。揭示了制造这些大麻素-聚乙二醇链的方法。
• USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
  申请人：GW Research Limited

  公开号：EP3735964A1

  公开（公告）日：2020-11-11

  The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

  本公开涉及使用大麻二酚（CBD）治疗失张力发作。尤其是大麻二酚在减少失张力癫痫发作方面似乎特别有效，这些患者的病因包括Lennox-Gastaut 综合征；结节性硬化综合征；Dravet 综合征；Doose 综合征；Aicardi 综合征；CDKL5 和 Dup15q。本公开进一步涉及 CBD 与一种或多种抗癫痫药物 (AED) 的联合使用。
• Pharmaceutical composition and method of manufacturing
  申请人：Speier Gary J.

  公开号：US10238705B2

  公开（公告）日：2019-03-26

  The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

  本发明提供了获得大麻植物材料提取物的方法，以及对提取物进行后续加工以提 供大麻浓缩物的方法。本发明还提供了包括大麻浓缩物（或提取物）的药物剂型（如口服薄膜和透皮贴剂），以及包括施用药物剂型的医疗方法。